Malaria Clinical Trial
Official title:
Efficacy and Bio-availability of Artemether-Lumefantrine Fixed Combination in Severely Malnourished Children Compared to Non-severely Malnourished Children
The general objective of the study is to answer to the question: "Is the current dose of AL less efficacious in the severely malnourished compared to the non-severely malnourished children, and is PK in cause?" We aim to assess whether the current treatment dose is adequate for children with severe acute malnutrition, and we hope results will guide further recommendations for malaria treatment in this specific population.
Study hypothesis:
We hypothesize that AL efficacy might be impaired in severely malnourished children, due to
impaired bio-availability of antimalarial drugs in this population.
Objectives:
The general objective of the study is to answer to the question: "Is the current dose of
Artemether-Lumefantrine (AL) less efficacious in the severely malnourished compared to the
non-severely malnourished children, because of impaired bio-availability?" We aim to assess
whether the current treatment dose should be adjusted for this specific population.
The primary objective of the study is to compare the rates of treatment failure (after PCR
correction) between severely malnourished and non-severely malnourished children.
The secondary objectives are:
- To compare the bio-availability of lumefantrine between severely malnourished and
non-severely malnourished children (AUC, concentration at day 7…)
- To compare other efficacy parameters (such as the rates of early parasitological
failure, early clinical failure, late therapeutic failure, reinfection and
recrudescence) and safety parameters between severely malnourished and non-severely
malnourished children.
- Additionally, If the rate of early parasitological failure appears high in severely
malnourished children, we will measure the bio-availability of the artemisinin
derivative and will compare it between severely malnourished and non-severely
malnourished children.
Settings:
This study will be conducted in two sites in Mali and Niger, two country most affected by
malaria and malnutrition, with a high malaria transmission roughly from July to December,
corresponding to the malnutrition peak.
Study population:
This study will enrol children with uncomplicated P. falciparum malaria aged between 6 and
59 months, according to the WHO standardized protocol for the surveillance of antimalarial
drug efficacy .
The definition of severe acute malnutrition will be weight-for-height <-3 z-scores to the
reference WHO 2006 growth standards or middle upper arm circumference (MUAC) <115 mm.
The definition of non-severe acute malnutrition will be a weight-for-height z-score ≥-3 and
MUAC ≥115 mm.
Severely stunted children (height-for-age z -score <-3) will be excluded from this study,
which is primarily focused on wasted children.
The following modifications of the inclusion criteria will be applied, compared to the
standardised WHO protocol:
- Decreased lower level of parasite density (PD) from 2000 to 1000 parasites per micro
litre, as previous studies showed frequent low parasitemias in these patients.
- In the malnourished children arms, malnutrition <-3 z-score will be an inclusion
criterion rather than an exclusion criterion.
- Children with complications of acute malnutrition needing intensive treatment will be
excluded.
Study procedures:
Children will be screened at the renutrition center and pediatric ward of each site.
Two non-malnourished children will be enrolled soon after the enrolment of each malnourished
child (ideally, during the same week), to allow carrying out inclusions in parallel for the
two study groups, with benefit in terms of representativeness of the study population
throughout the malaria season. The ratio of 2 non-severely malnourished children for 1
severely malnourished has been chosen to lower the total number of severely malnourished
children to be recruited.
Treatment intake will be supervised and children will be followed-up for 42 days, according
to the WHO standardized protocol4. PCR will be used to distinguish recrudescence and
re-infection.
In malnourished children, the standardized nutritional rehabilitation program will also be
conducted in parallel, and weekly follow-up will include the assessment of nutritional
rehabilitation.
Treatment adverse events will be monitored and a Data Safety Monitory Board (DSMB) will be
instituted.
To assess the bio-availability of the study drugs, a population pharmacokinetics approach
will be used to reduce the number of blood sampling. Capillary blood will be collected on
filter paper for measurement of lumefantrine concentrations, 5 times between Day 0 and day
7. Assays will use a liquid chromatography technique with tandem mass spectrometry.
Statistical considerations:
Efficacy analysis:
The primary analysis will compare the efficacy of AL in malnourished children versus
non-malnourished children.
It will be designed to detect a minimum crude difference of 8% in Adequate Clinical and
Parasitological Response (ACPR) rate in the population of malnourished children (87% versus
95% in non-malnourished children for both treatment combinations), with a statistical power
of 80% and a 2-sided significance level of 5%. 160 severely malnourished children and 320
non-severely malnourished children will be enrolled. An additional 10% will be added to
account for losses to follow-up and exclusions, yielding to 180 malnourished children and
360 non-malnourished children for each treatment evaluated. To summarize, a total of 540
children will be recruited as a whole.
To answer to the primary objective of the study, we will use multivariate models in which
ACPR will be explained by malnutrition status after adjustment for baseline parasitemia,
age, and other baseline characteristics that differ between the two populations of children.
Cox proportional hazards models and logistic regression models will be used.
Pharmacokinetics (PK) analysis:
A population pharmacokinetics approach will be used, according to the WHO guidelines
recommending 5 sampling windows for lumefantrine. Ideally, each sampling window should
contain an equal number of samples randomly distributed over the duration of the window.
Alternatively, we will use fixed, pre-determined sampling times within the suggested
windows, which will fit other samplings required by the protocol. The 5 blood samples will
be collected in the 180 severely malnourished children enrolled, and in 180 non-severely
malnourished children (randomly chosen), which will allow us to obtain data representative
of the studied populations5.
To limit blood sampling in severely malnourished children, we choose to initially restrict
the PK assessment to lumefantrine, which exposure is the most correlated to overall
treatment response5.
We will have the possibility to add the dosage of artemisinin derivatives in a second phase,
in case of "relatively high" observed rate of early parasitological failures or impaired
parasite clearance. Indeed, the main pharmacodynamics effect initially (during the first 3
days of treatment) is that of the artemisinin component5. If parasites are still present at
day 3, it could be due to under-exposure to the artemisinin component. Otherwise, there is
no reason to suspect such under-exposure.
The DSMB will have the responsibility to monitor closely all cases of early parasitological
failure, and to recommend adding artemether PK assessment if they reckon that the rate is
"unexpectedly high".
PK data will be analysed using nonlinear mixed-effects modelling (with external
partnership).
Benefits and risks:
Benefit for the participants will be to receive free of charge treatment for a confirmed
diagnosis of malaria. Participants will also benefit from regular visits that will ensure
that the treatment cleared the malaria infection and any recurrent malaria episode or
emergence of new diseases will be treated quickly. Malnourished patients will benefit from
the standardized nutritional rehabilitation program.
The child will be asked to come to the study site for regular check and will be exposed to a
series of blood sampling that would not happen if he was not enrolled in the study.
Ethical and regulatory considerations:
The study has been funded by the MSF innovative fund. The protocol is submitted to the
approval of MSF Ethics Review Board and the Malian Institutional Ethics Committee.
A DSMB will closely monitor early parasitological failures, and follow serious adverse
events.
An external monitoring will be performed during the study.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02527005 -
A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients
|
Phase 1 |